2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150Sermorelin and ipamorelin are investigational peptides that stimulate endogenous growth hormone release through complementary GHRH and ghrelin receptor pathways. Preclinical and physiological data support synergistic GH pulsatility when both signaling axes are engaged, though direct combination studies remain limited.
Sermorelin is a synthetic peptide analog of growth hormone–releasing hormone (GHRH), corresponding to the first 29 amino acids of endogenous human GHRH [1].
Sermorelin acts on the anterior pituitary and stimulates pulsatile secretion of growth hormone (GH). This preserves endogenous regulatory feedback mechanisms and the natural circadian rhythm of GH release.
In research and clinical studies, sermorelin has been used as a tool to assess pituitary GH reserve and to explore age-related or functional declines in GH signaling.
By activating the GHRH receptor, sermorelin promotes downstream effects on IGF-1 production, protein synthesis, and metabolic regulation [2], [3].
Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue that acts primarily through the ghrelin (GHS-R1a) receptor in the pituitary and hypothalamus [4].
Unlike other GH secretagogues, ipamorelin is designed to stimulate growth hormone release with minimal impact on other pituitary hormones, such as cortisol or prolactin.
Preclinical and early human studies indicate that ipamorelin promotes physiologic, pulsatile GH secretion without significantly increasing appetite or activating broad stress pathways.
Because it acts through a receptor pathway distinct from GHRH, ipamorelin is investigated for its complementary role in modulating endogenous GH signaling.
Sermorelin and ipamorelin are often grouped together because they stimulate growth hormone release through distinct, yet convergent methods in the somatotropic axis.
Sermorelin activates the GHRH receptor on pituitary somatotrophs, activating cAMP/PKA signaling to promote pulsatile GH secretion [5].
Ipamorelin, by contrast, is a ghrelin receptor (GHS-R1a) agonist, which activates complementary intracellular pathways (PLC/IP3/Ca²+-linked signaling) that also facilitate GH release [6].
The rationale for synergy is not simply "two peptides = more GH," but rather that GHRH and ghrelin/GHS signaling amplify each other's downstream effects at the pituitary and hypothalamic level.
Experimental work shows that ghrelin and growth hormone secretagogues can potentiate GHRH-driven signaling responses in model systems expressing both receptors [7].
In addition, mechanistic studies have reported receptor-level and pathway-level cross-talk between GHRH-related signaling and ghrelin receptor biology, creating a plausible basis for amplified GH pulsatility when both pathways are engaged [8].
From a systems perspective, this pairing can be framed as:
Direct, peer-reviewed studies that specifically test sermorelin (GHRH 1–29) combined with ipamorelin as a named pairing are limited.
However, there is evidence for class-level synergy (GHRH analogs used with ghrelin/GHS receptor agonists) showing amplified GH responses compared with either pathway alone.
An in vitro study examined how GHRH and growth hormone secretagogues (GHS), like ghrelin, interact at the cellular signaling level to regulate growth hormone (GH) release [7].
A heterologous cell system expressing cloned, epitope-tagged GHRH and GHS receptors were given GHRH alone, GHS or ghrelin alone, or combined receptor activation. Effects were tracked through cAMP production and pathway-specific pharmacologic inhibition.
Results showed that:
The results show a selective and receptor-specific synergy between GHRH and GHS receptors, amplifying cAMP signaling beyond what GHRH alone produces.
Given this in vitro evidence, the sermorelin–ipamorelin rationale is therefore best presented as mechanistic extrapolation rather than as a conclusively proven combination therapy.
From a research design standpoint, a 1:1 mass ratio (5 mg + 5 mg or 10 mg + 10 mg) can be framed as aiming to engage both upstream control systems, GHRH receptor signaling and GHS-R1a signaling, without over-weighting one pathway at the expense of the other.
Beyond that general rationale, the optimal ratio has not been established in the open literature and should be treated as an empirical parameter rather than a settled standard.
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Sermorelin + Ipamorelin is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Every lot undergoes our 6-panel testing protocol: identification by ESI-MS, purification by RP-HPLC, conformity, sterility screening, quantification of net peptide content, and LAL endotoxin screening. Full analytical data is published in the Certificate of Analysis for each lot.
Lyophilized peptides should be stored at -20°C or below for long-term stability. Once reconstituted, peptides should be stored at 2–8°C and used within a reasonable timeframe depending on the specific compound. Avoid repeated freeze-thaw cycles. Always store in a dry environment away from direct light.
Orders are processed within 1–3 business days after payment confirmation. Orders placed after 3:00 PM Pacific time or on weekends and holidays will begin processing the next business day. We offer free standard shipping on orders over $150. All orders are shipped in insulated packaging with ice packs when necessary. Standard delivery typically takes 2–4 business days within the continental US.
No. All compounds sold by Genesis Peptides are strictly for in vitro and preclinical laboratory research purposes only. They are not approved for human consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm the products will be used solely for legitimate research applications.
A Certificate of Analysis (COA) is a document issued by our analytical laboratory that reports the results of all quality control tests performed on a specific lot of product. Each COA includes HPLC chromatograms, mass spectra, endotoxin results, and quantification data where applicable. COAs are available in our COA Library for every lot we have shipped.
Yes. We offer volume pricing for universities, research institutions, and laboratories with recurring needs. Discounts begin at 100+ units and scale with volume. Contact our team for a custom quote tailored to your research requirements.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.